Cytogenetic, interphase fluorescent in situ hybridization (FISH) and RT-PCR methods were used to study minimal residual disease in peripheral blood stem cells collected for autografting in three chronic myeloid leukemia (CML) patients in sustained complete cytogenetic remission after treatment with interferon ␣ (IFN␣). Karyotypic analysis failed to reveal Ph-positive metaphases. FISH detected 9-16% nuclei with a BCR-ABL fusion gene, contrasting with RT-PCR, performed in two cases, which was negative in one case and weakly positive in the other. RT-PCR was also subsequently weakly positive in the third patient. This discrepancy suggests that the BCR-ABL genomic rearrangement persists unexpressed in quiescent cells. These preliminary results, which need to be confirmed in larger series, suggest that monitoring residual disease in CML should be performed both at DNA and RNA levels. Moreover, autografting following IFN␣ therapy should be considered with caution because of the persistence of the BCR-ABL genomic rearrangement in a sizeable proportion of the cells.
Introduction
Chronic myeloid leukemia (CML) is a hematologic malignancy arising from the monoclonal expansion of a pluripotent hematopoietic stem cell. CML is characterized in more than 90% of patients by a reciprocal translocation between chromosomes 9 and 22, translocation t(9;22)(q34;q11), which is referred to as the Philadelphia (Ph) chromosome. 1, 2 At the molecular level, the Ph chromosome is the result of a rearrangement between the ABL gene located on chromosome 9 and the breakpoint cluster region (BCR) on chromosome 22 forming an hybrid BCR-ABL gene, which is a specific marker of the disease. 3, 4 An interesting advance in the treatment of CML was the introduction of interferon ␣ (IFN␣) therapy. Recent studies have shown that treatment with IFN␣ is able to induce clinical remission with a complete cytogenetic response in up to 15% of patients treated at diagnosis. 5 Moreover, when the response to IFN␣ was monitored by quantitative reverse transcriptasepolymerase chain reaction (RT-PCR), some patients achieved a molecular remission which is thought to be complete when only very low amounts of BCR-ABL mRNA are detected. 6, 7 In such cases the question of maintenance therapy remains unresolved. The frequent side-effects of IFN␣ therapy led to consideration of the possibility of the arrest of treatment followed by autografting using Ph-negative blood progenitor cells collected by leukapheresis. 8, 9 Hence, the definition of complete remission must be as accurate as possible. In the current study, we used cytogenetic interphase fluorescent in situ hybridization (FISH) and RT-PCR methods to study mini- 
Materials and methods

Patients
Bone marrow aspirates and/or peripheral blood from the three patients (two men and one woman, aged 27-46 years) were studied at the time of diagnosis and during the course of the disease by standard cytogenetic methods and RT-PCR. All three patients were in first chronic phase at diagnosis with 100% Ph-positive metaphases. RT-PCR revealed a b3a2 transcript in all three cases ( Table 1 ). The details of the treatment regimen have been previously reported. 5 Hydroxyurea and IFN␣ were given simultaneously. Hydroxyurea was discontinued when a complete and stable hematologic remission was achieved. Monthly courses of low-dose cytarabine were added to IFN␣ in cases 1 and 2 whereas in the third case IFN␣ was given alone. All three patients achieved a sustained complete cytogenetic remission. For the collection of blood stem cells as well as for the biological studies, informed consent was given by all patients.
Mobilization and collection of peripheral blood stem cells
Because autografting could be considered in case of cytogenetic relapse, peripheral blood cells were collected by leukapheresis. Patients were treated with recombinant human granulocyte colony-stimulating factor (rHuG-CSF) (5 g/ kg/day) while continuing IFN␣. Stem cell harvest was performed from day 5 of rHuG-CSF therapy for 4 consecutive days until yielding at least 6 × 10 8 mononuclear cells/kg of the body weight of the patients.
Chromosome and FISH analysis
Chromosome and FISH analysis were performed using bone marrow cells collected just before rHuG-CSF administration and with an aliquot of every leukapheresis product. Chromosome analysis was performed according to the R-banding method after short (24 and 48 h) cultures without addition of mitogens from an aliquot of every leukapheresis product. FISH analysis for the BCR-ABL fusion gene was performed using probes for the ABL oncogene and the M-BCR region (Oncor, Gaithersburg, MD, USA) to detect t(9;22)(q34;q11) in interphase cells as described by Tkachuk et al. 10 FISH was performed using bone marrow samples collected before leukapheresis and leukapheresis products. Both were directly processed and cultures were performed only for cytogenetic studies. Hybridization was identified by a green fluorescent spot with the ABL probe and by a red spot with the BCR gene. The BCR-ABL fusion gene produced a colocalization of one red and one green signal often leading to a yellow spot in interphase nuclei. Cells were scored as positive when BCR and ABL signals were overlapping or touching. 11 Slides were independently examined by two observers and for each specimen 200 nuclei were scored. Only interphase nuclei in which it was possible to account for both copies of the BCR and ABL probes were scored, which led us to exclude a mean of 15% nuclei which were considered as not evaluable. The final result was expressed as the percentage of nuclei with an apparent BCR-ABL fusion signal. Negative FISH controls included bone marrow samples from four healthy volunteers, four Ph-negative myeloproliferative disorders and leukapheresis products from three other healthy volunteers. Positive controls were also performed on 24 h bone marrow cultures of three CML patients' cells in complete cytogenetic response but positive by RT-PCR. False positive results were obtained in 3-6% of interphase nuclei from normal bone marrow and leukapheresis samples. The results of Ph-negative myeloproliferative disorders were virtually superimposable on those observed with normal controls. The cut-off limit for BCR-ABL positivity was set at the mean of normal results +3 s.d., ie 7.5%. In contrast, mean 17% positive nuclei were found in the three complete cytogenetic responders with a positive RT-PCR.
Amplification of BCR-ABL mRNA by polymerase chain reaction Total leukocyte RNA was prepared either from 15 ml of peripheral blood during the course of the disease or from leukapheresis products (in cases 1 and 2). Mononuclear cells were obtained after Ficoll-Hypaque centrifugation and RNA extraction was performed according to Chomczynski and Sacchi. 12 RNA samples were aliquoted in small volumes (50 l) and controlled by electrophoresis on 1% agarose gel. Reverse transcription, qualitative and quantitative PCR for ABL-mRNA and p210 BCR-ABL-mRNA were performed as described by Cross et al. 13 All cDNAs were analyzed by qualitative double-step RT-PCR for BCR-ABL using an ABL amplification as an internal control. In the most recent samples, BCR-ABL-mRNAs were quantitated by a double-step competitive PCR, and ABLmRNA by a single-step competitive PCR according to a standardized protocol using serial dilutions of a p120 competitor ranging from 1 to 10 7 molecules. 7 Results were expressed as the BCR-ABL/ABL mRNA ratio. In our hands, the method is able to detect three BCR-ABL transcript molecules in the assay. Therefore, the sensitivity of the amplification can be expressed by a BCR-ABL/ABL ratio close to 0.002%. Among the CML patients treated with IFN␣, we have isolated a group qualified as complete responders in which all patients are Phnegative with a BCR-ABL/ABL mRNA ratio lower than 0.05%. The three patients in the present study belong to this group.
Results
A complete cytogenetic response was achieved after IFN␣ therapy of 18, 24 and 9 months duration, respectively. Subsequent karyotypes were negative in cases 1 and 2 in 22 further samples (681 Ph-negative metaphases) and 19 further samples (521 Ph-negative metaphases), respectively. In the third patient, a single Ph-positive metaphase was found out of 38 in a single sample among 19 further samples and a total of 568 metaphases (previous results had been consistently negative during the 4 years preceding leukapheresis). Hence, at the time of leukapheresis, the three patients were in complete cytogenetic remission that lasted for 78, 82 and 87 months, respectively (Figure 1) .
Cytogenetic studies failed to detect Ph + metaphases from bone marrow cultures performed just before leukapheresis and from every leukapheresis product cultures after examination of 124-131 metaphases in the four leukapheresis products in each case. Surprisingly, FISH studies detected a percentage of BCR-ABL fusion gene ranging from 9 to 16% nuclei (mean 12%) in leukapheresis products and bone marrow cells collected just before leukapheresis. Subsequent karyotypes were negative in five (cases 1 and 2) and six (case 3) further samples whereas FISH performed in cases 1 and 2 remained positive with a mean of 10% of positive nuclei 2 years after leukapheresis.
RT-PCR was performed five times in case 1 and four times in the other two during the 3 years preceding leukapheresis. In patient 1, RT-PCR was weakly positive in the first experiment, negative in the three further ones and weakly positive (Ͻ0.06%) before leukapheresis. Before leukapheresis, in cases 2 and 3, BCR-ABL RT-PCR was negative in case 2 and weakly positive in case 3 with a low BCR-ABL/ABL mRNA ratio (0.3%). RT-PCR performed in cases 1 and 2 from leukapheresis products was negative in case 1 and weakly positive in case 2 with a BCR-ABL/ABL mRNA ratio Ͻ0.005%. During the 2 years following leukapheresis, the BCR-ABL fusion mRNA remained consistently undetectable in case 1 and weakly positive in the other two with a very low BCR-ABL/ABL ratio ( Figure 1 and Table 2 ).
Discussion
The management of patients with CML has become complex in recent years, with three possible therapeutic options including IFN␣, allografting or autografting. A significant survival benefit has been recently demonstrated among patients receiving IFN␣ in combination with cytarabine. 5 However, in most cases, RT-PCR detects BCR-ABL transcripts and there is no agreement regarding duration and dose of IFN␣ therapy. Another approach in Ph-negative patients could be to collect peripheral progenitor stem cells for autografting. 9 In the present study of three cases of Ph-negative CML after IFN␣ therapy, we investigated residual disease in leukapheresis products. Conventional cytogenetic analysis was normal in all three cases. In contrast, interphase FISH detected a fusion gene in every case and in every leukapheresis product with a percentage of positive nuclei ranging from 9 to 16%. This discrepancy is not surprising since cytogenetic study only analyzes cycling cells and a small number of metaphases. The percentage of FISH-positive cells must be interpreted with caution because of results in normal controls (normal bone marrow cells, leukapheresis products and Ph-negative myeloproliferative syndromes processed in the same way) showing false positivity in 3-6% of nuclei which is similar to previous reports.
14,15 Indeed, it is well known that fortuitous juxtapositions of red and green spots may result in an apparently fused signal. 11 However, the slides derived from normal and CML samples were independently examined by two of us without knowledge of the diagnosis and both examiners were able to identify the CML material. It must be emphasized that only overlapping or touching red and green signals were scored as positive 11 and in every patient and every experiment, the percentage of interphase FISH-positive cells was clearly higher than in controls with a yellow signal indicating a real fusion gene in every experiment whereas such a signal was never observed in controls. By using a triple-probe threecolor FISH system, Sinclair et al 16 improved the sensitivity of BCR-ABL detection but this method was not available at the time of our study. Another possibility was to look for the translocation at the DNA level by Southern blotting, but no DNA was available. In any case, the sensitivity of Southern blotting is unlikely to be able to evidence a BCR-ABL rearrangement in our three patients (mean 12% positive nuclei in the patients and 7.5% false positive nuclei in normal controls). We recently studied uncultured blood and bone marrow samples from patient 2 by FISH using probes which recognize the reciprocal translocation and show two fusion signals (dual BCR-ABL probes; Oncor). Under these conditions, no falsepositive cells were detected in normal controls whereas 3% of patient 2's cells showed clearly positive fusion signals, which is in accordance with the previous data.
More surprisingly, RT-PCR, the most sensitive procedure for the detection of BCR-ABL mRNA, was found to be negative in one case and weakly positive in another. In contrast, interphase FISH was clearly positive suggesting that a significant number of cells harbor the BCR-ABL translocation but do not significantly express BCR-ABL mRNA. During subsequent studies performed during a 2-year period, RT-PCR remained negative (case 1) or very weakly positive (cases 2 and 3). Such discordances between cytogenetics or FISH or Southern blot and RT-PCR have already been mentioned in previous studies. 14, 15, [17] [18] [19] [20] [21] [22] In most of these reports, studies were performed after cultures of hematopoietic progenitor cells from untreated patients with CML 14, 15, 17, 18, 22 and it has been suggested that the BCR-ABL translocation was present in the most primitive hematopoietic progenitor cells which might have been quiescent and transcriptionally silent.
RT-PCR, genomic DNA-PCR, cytogenetics and FISH have also been used to detect residual disease after treatment with IFN␣ 20 or allogeneic bone marrow transplantation.
20,21,23
Zhang et al 23 compared amplification of genomic BCR-ABL fusion DNA with conventional RT-PCR in cells from 10 CML patients who underwent an allogeneic bone marrow transplantation. They found three RT-PCR negative patients in whom genomic DNA-PCR was positive. This is in keeping with the present study in which three complete cytogenetic responders were found FISH positive whereas RT-PCR was negative or weakly positive. The reason for the probable persistence of a significant percentage of quiescent malignant cells in patients treated with IFN␣ in apparently complete remission is unclear. IFN␣ exerts various activities on cellular proliferation and immunoregulation. 24, 25 Recent investigations revealed that IFN␣ is able to down-modulate E2F activity.
26
E2F is a transcription factor of genes involved in the progression of the cell cycle and it is conceivable that a decreased expression of E2F might maintain malignant cells in a quiescent state. The persistence of BCR-ABL untranscribed DNA might reflect an effect of E2F on the expression of the fusion gene.
The present results are preliminary but they could have at least two implications for patients' follow-up and treatment. Competitive RT-PCR using an internal control is considered as the most sensitive method to monitor Ph-negative CML patients under IFN␣ therapy, 6, 7 but quiescent malignant cells appear to persist in the absence of significant levels of BCR-ABL transcripts. The three patients under study are currently in sustained cytogenetic remission for about 10 years which suggests that the quiescent state may be stable. However, it remains possible that the rearranged cells might enter into the cell cycle leading to the expansion of the malignant clone. On the other hand, the presence of malignant cells expressing very low levels of BCR-ABL transcript should have important therapeutic implications. Indeed, autografting following IFN␣ therapy should be considered with caution, even after selective inhibition of Ph-positive progenitors by antisense oligodeoxynucleotides in vitro, because antisense oligonucleotides targeted against BCR-ABL mRNA may be unable to eradicate Ph-positive cells that do not transcribe the fusion gene. A possible strategy could be to maintain low doses of IFN␣ after autografting to avoid the entry of malignant residual cells into the cell cycle. In conclusion, our preliminary results need to be confirmed in a larger series, but it seems presently useful to monitor minimal residual disease in CML at both the DNA and RNA levels.
